Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord

Chêne, Geneviève; Phillips, Andrew; Costagliola, Dominique; Sterne, Jonathan A C; Furrer, Hansjakob; Amo, Julia del; Mocroft, Amanda; Monforte, Antonella d’Arminio; Dabis, François; Miró, José M.; Barger, Diana; Termote, Monique; Schwimmer, Christine; Brandt, Rikke Salbøl; Friis-Møller, Nina; Raben, Dorthe; Haerry, David; Egger, Matthias; Weller, I. V. D.; Wit, Stéphane De

doi:10.1093/ije/dyw211

Cited by 28 publications

(25 citation statements)

References 26 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For the IeDEA Southern Africa region, we restricted the analysis to two cohorts from South Africa that reduced under‐reporting of cancer cases in the HIV cohorts through record linkages with the National Cancer Registry . COHERE is a collaboration of observational HIV cohorts across Europe . It contributed data from 24 cohorts, covering 36 countries.…”

Section: Methodsmentioning

confidence: 99%

Cervical cancer risk in women living with HIV across four continents: A multicohort study

Rohner

Bütikofer

Schmidlin

et al. 2019

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

We compared invasive cervical cancer (ICC) incidence rates in Europe, South Africa, Latin and North America among women living with HIV who initiated antiretroviral therapy (ART) between 1996 and 2014. We analyzed cohort data from the International Epidemiology Databases to Evaluate AIDS (IeDEA) and the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord. We used flexible parametric survival models to determine regional ICC rates and risk factors for incident ICC. We included 64,231 women from 45 countries. During 320,141 person‐years (pys), 356 incident ICC cases were diagnosed (Europe 164, South Africa 156, North America 19 and Latin America 17). Raw ICC incidence rates per 100,000 pys were 447 in South Africa (95% confidence interval [CI]: 382–523), 136 in Latin America (95% CI: 85–219), 76 in North America (95% CI: 48–119) and 66 in Europe (95% CI: 57–77). Compared to European women ICC rates at 5 years after ART initiation were more than double in Latin America (adjusted hazard ratio [aHR]: 2.43, 95% CI: 1.27–4.68) and 11 times higher in South Africa (aHR: 10.66, 95% CI: 6.73–16.88), but similar in North America (aHR: 0.79, 95% CI: 0.37–1.71). Overall, ICC rates increased with age (>50 years vs. 16–30 years, aHR: 1.57, 95% CI: 1.03–2.40) and lower CD4 cell counts at ART initiation (per 100 cell/μl decrease, aHR: 1.25, 95% CI: 1.15–1.36). Improving access to early ART initiation and effective cervical cancer screening in women living with HIV should be key parts of global efforts to reduce cancer‐related health inequities.

show abstract

Section: Methodsmentioning

confidence: 99%

Cervical cancer risk in women living with HIV across four continents: A multicohort study

Rohner

Bütikofer

Schmidlin

et al. 2019

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Individuals included in this study were enrolled in observational HIV cohorts participating in the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE). COHERE is a collaboration of 40 cohorts across Europe and is part of the EuroCoord network . Our analyses were based on data pooled in the COHERE in EuroCoord merger in July 2015.…”

Section: Methodsmentioning

confidence: 99%

Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co‐infected HIV patients with cirrhosis

Willemse

Smit²,

Sogni

et al. 2019

Journal of Viral Hepatitis

Self Cite

View full text Add to dashboard Cite

“…IeDEA is a global consortium with regional centres that pool clinical and epidemiological data on individuals living with HIV; regions collecting paediatric data are Caribbean/Central and South America, Asia‐Pacific, East Africa, West Africa, Central Africa and Southern Africa . COHERE is a collaboration of European HIV cohorts that conducts epidemiological research on the prognosis of people living with HIV across Europe . IMPAACT 219C and PHACS AMP are US‐based prospective cohort studies designed to evaluate the impact of HIV infection and cART on youth.…”

Section: Methodsmentioning

confidence: 99%

Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral therapy in an era of changing criteria for treatment initiation

Cohere

Phacs

2018

J Intern AIDS Soc

Self Cite

View full text Add to dashboard Cite

IntroductionThe CD4 cell count and percent at initiation of combination antiretroviral therapy (cART) are measures of advanced HIV disease and thus are important indicators of programme performance for children living with HIV. In particular, World Health Organization (WHO) 2017 guidelines on advanced HIV disease noted that >80% of children aged <5 years started cART with WHO Stage 3 or 4 disease or severe immune suppression. We compared temporal trends in CD4 measures at cART start in children from low‐, middle‐ and high‐income countries, and examined the effect of WHO treatment initiation guidelines on reducing the proportion of children initiating cART with advanced disease.MethodsWe included children aged <16 years from the International Epidemiology Databases to Evaluate acquired immunodeficiency syndrome (AIDS) (IeDEA) Collaboration (Caribbean, Central and South America, Asia‐Pacific, and West, Central, East and Southern Africa), the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE), the North American Pediatric HIV/AIDS Cohort Study (PHACS) and International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) 219C study. Severe immunodeficiency was defined using WHO guidelines. We used generalized weighted additive mixed effect models to analyse temporal trends in CD4 measurements and piecewise regression to examine the impact of 2006 and 2010 WHO cART initiation guidelines.ResultsWe included 52,153 children from fourteen low‐, eight lower middle‐, five upper middle‐ and five high‐income countries. From 2004 to 2013, the estimated percentage of children starting cART with severe immunodeficiency declined from 70% to 42% (low‐income), 67% to 64% (lower middle‐income) and 61% to 43% (upper middle‐income countries). In high‐income countries, severe immunodeficiency at cART initiation declined from 45% (1996) to 14% (2012). There were annual decreases in the percentage of children with severe immunodeficiency at cART initiation after the WHO guidelines revisions in 2006 (low‐, lower middle‐ and upper middle‐income countries) and 2010 (all countries).ConclusionsBy 2013, less than half of children initiating cART had severe immunodeficiency worldwide. WHO treatment initiation guidelines have contributed to reducing the proportion of children and adolescents starting cART with advanced disease. However, considerable global inequity remains, in 2013, >40% of children in low‐ and middle‐income countries started cART with severe immunodeficiency compared to <20% in high‐income countries.

show abstract

Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord

Cited by 28 publications

References 26 publications

Cervical cancer risk in women living with HIV across four continents: A multicohort study

Cervical cancer risk in women living with HIV across four continents: A multicohort study

Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co‐infected HIV patients with cirrhosis

Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral therapy in an era of changing criteria for treatment initiation

Contact Info

Product

Resources

About